Monoclonal antibodies directed to IL-1 activated endothelial cells and medicaments employing the monoclonal antibodies
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Apr 30, 1991
Grant Date -
N/A
app pub date -
May 23, 1989
filing date -
May 23, 1989
priority date (Note) -
Expired
status (Latency Note)
Importance
Abstract
Hybridoma cell lines are made that produce monoclonal antibodies having, among others, the following identifying characteristics: (1) bind to IL-1 activated endothelial cells; (2) do not bind significantly to normal resting endothelial cells; (3) do not bind significantly to normal resting or IL-1 activated epidermal keratinocytes or resting or IL-1 activated fibroblasts. The monoclonal antibodies are used in therapeutic compositions for blocking inflammatory responses associated with activated endothelial cells.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully